Literature DB >> 25546781

Immunoglobulin G Fc N-glycosylation in Guillain-Barré syndrome treated with intravenous immunoglobulin.

W-J R Fokkink1, M H C Selman, M Wuhrer, B C Jacobs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25546781      PMCID： PMC4285510          DOI： 10.1111/cei.12530

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  13 in total

1.  A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group.

Authors:  F G van der Meché; P I Schmitz
Journal:  N Engl J Med       Date:  1992-04-23       Impact factor: 91.245

2.  Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation.

Authors:  Yoshikatsu Kaneko; Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Science       Date:  2006-08-04       Impact factor: 47.728

3.  Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc.

Authors:  Robert M Anthony; Falk Nimmerjahn; David J Ashline; Vernon N Reinhold; James C Paulson; Jeffrey V Ravetch
Journal:  Science       Date:  2008-04-18       Impact factor: 47.728

Review 4.  Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

Authors:  Inessa Schwab; Falk Nimmerjahn
Journal:  Nat Rev Immunol       Date:  2013-02-15       Impact factor: 53.106

5.  Association between galactosylation of immunoglobulin G and improvement of rheumatoid arthritis during pregnancy is independent of sialylation.

Authors:  Albert Bondt; Maurice H J Selman; André M Deelder; Johanna M W Hazes; Sten P Willemsen; Manfred Wuhrer; Radboud J E M Dolhain
Journal:  J Proteome Res       Date:  2013-09-24       Impact factor: 4.466

Review 6.  Intravenous immunoglobulin for Guillain-Barré syndrome.

Authors:  Richard A C Hughes; Anthony V Swan; Pieter A van Doorn
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

7.  Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome.

Authors:  Krista Kuitwaard; Jenny de Gelder; Anne P Tio-Gillen; Wim C J Hop; Teun van Gelder; Albert W van Toorenenbergen; Pieter A van Doorn; Bart C Jacobs
Journal:  Ann Neurol       Date:  2009-11       Impact factor: 10.422

8.  Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial.

Authors:  R van Koningsveld; P I M Schmitz; F G Avander Meché; L H Visser; J Meulstee; P A van Doorn
Journal:  Lancet       Date:  2004-01-17       Impact factor: 79.321

Review 9.  Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome.

Authors:  Pieter A van Doorn; Liselotte Ruts; Bart C Jacobs
Journal:  Lancet Neurol       Date:  2008-10       Impact factor: 44.182

Review 10.  Terminal sugars of Fc glycans influence antibody effector functions of IgGs.

Authors:  T Shantha Raju
Journal:  Curr Opin Immunol       Date:  2008-07-17       Impact factor: 7.486
View more
  4 in total

Review 1.  Immunoglobulin G N-glycan Biomarkers for Autoimmune Diseases: Current State and a Glycoinformatics Perspective.

Authors:  Konstantinos Flevaris; Cleo Kontoravdi
Journal:  Int J Mol Sci       Date:  2022-05-06       Impact factor: 6.208

Review 2.  Biological roles of glycans.

Authors:  Ajit Varki
Journal:  Glycobiology       Date:  2016-08-24       Impact factor: 4.313

Review 3.  Sialylated immunoglobulin G: a promising diagnostic and therapeutic strategy for autoimmune diseases.

Authors:  Danqi Li; Yuchen Lou; Yamin Zhang; Si Liu; Jun Li; Juan Tao
Journal:  Theranostics       Date:  2021-03-13       Impact factor: 11.556

4.  Acute lyme disease IgG N-linked glycans contrast the canonical inflammatory signature.

Authors:  Benjamin Samuel Haslund-Gourley; Stéphane Grauzam; Anand S Mehta; Brian Wigdahl; Mary Ann Comunale
Journal:  Front Immunol       Date:  2022-08-05       Impact factor: 8.786
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.